



## News Release

### **Suven spends 22% of revenue on R&D PAT up by 58% for the 1st Quarter**

**HYDERABAD, INDIA (July 27 2010)** – SUVEN LIFE Sciences Limited, a biopharmaceutical company specializing in drug discovery and developmental activities in Central Nervous System disorders, today announced its audited financial results for the quarter ended June' 2010. The audited financial results were reviewed by the audit committee and approved by the Board of Directors in their meeting held on July 27, 2010 at Hyderabad.

#### **Financial Highlights for the quarter ended Mar' 2010:**

Growth in revenue 16.05% (Rs 363 mil vs. Rs 313 mil)  
Growth in PAT 57.76% (Rs 34.5 mil vs. Rs 21.8 mil)  
Growth in EBIDTA 2.25% (Rs 45.6 mil vs. Rs 44.5 mil)  
Increase in R&D costs 13.16% (Rs.76.8 mil vs. Rs.67.9 mil)

Suven's major thrust on innovative R&D in Drug Discovery continues with a spending of Rs 76.8 mil (22% on revenue) for the quarter ended June 2010 which lead to increase in R&D costs by 13%.

During the quarter there were major qualitative achievements in securing 10 product patents from various countries like Australia, Canada, Eurasia, India, Japan and New zeeland.

The following are the updates of the Annual General Meeting held on July 27, 2010:

- Approved for the payment of dividend of Rs 0.25 (25%) per equity share of Rs 1 each.
- Approved and authorized the Board to raise funds not exceeding US\$ 50 million through issue of ADR/GDR/FCCB or other securities through international or domestic offerings.

Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class therapies through the use of GPCR targets. **The Company has twelve (12) internally-discovered therapeutic drug candidates** currently in pre-clinical stage of development targeting conditions such as ADHD, Dementia, Depression, Huntington's disease, Parkinson's disease and obesity in addition to **developmental candidate SUVN-502 for Alzheimer's disease and Schizophrenia.**

For more information on Suven/ACT, please visit our Web site at <http://www.suven.com>

#### **Risk Statement:**

***Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive;***